NICE recommends Amgen’s Imlygic for advanced skin cancer

pharmafile | August 9, 2016 | News story | Manufacturing and Production, Sales and Marketing Amgen, Imlygic, NICE, skin cancer 

NICE has published its final draft guidance recommending Amgen’s Imlygic (talimogene laherparepvec) for the treatment of advanced melanoma in adults that has spread and can no longer be surgically removed.

This decision comes after the organisation rejected the drug on the grounds of lack of efficacy evidence earlier this year.

The drug, derived from a herpes virus, is a new immunotherapy treatment to be injected directly into tumours; experts suggest it would be a suitable treatment for around 10-15% of advanced melanoma sufferers. NICE now recommends the drug for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: treatment with systemic immunotherapies is not suitable and; the company provides it with the discount agreed in the patient access scheme.

The drug had already received approval from the European Commission and the FDA.  

Matt Fellows

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

NICE shares draft guidance for AI’s use in radiotherapy treatment planning

The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine …

Latest content